Novartis Flags Entresto Risk as MSN Seeks to Delist Patent (1)

Novartis AG and MSN Laboratories Pvt. Ltd. sent a federal judge competing letters clashing over whether the district court must wait for MSN’s push to get a key patent for Novartis’ Entresto delisted from the FDA’s approved-drugs registry before issuing a final judgment.

The letters, filed Tuesday in the US District Court for the District of Delaware, came hours after the US Court of Appeals for the Federal Circuit denied MSN’s petitions for rehearings on its January order that barred MSN from launching its generic version of Novartis’s blockbuster heart-failure drug.

The Federal Circuit’s mandate, which will formalize the decision ...